S&P 500   4,620.31 (+0.35%)
DOW   36,356.12 (+0.30%)
QQQ   395.62 (+0.88%)
AAPL   192.82 (-1.48%)
MSFT   369.84 (-1.17%)
META   324.46 (-2.49%)
GOOGL   132.52 (-1.83%)
AMZN   145.93 (-1.01%)
TSLA   240.35 (-1.43%)
NVDA   469.11 (-1.25%)
NIO   7.69 (+4.20%)
BABA   71.49 (-0.90%)
AMD   134.39 (+4.24%)
T   16.69 (-1.36%)
F   11.13 (+1.09%)
MU   78.44 (+4.64%)
CGC   0.76 (-5.50%)
GE   120.17 (-0.35%)
DIS   92.16 (-0.71%)
AMC   7.08 (+2.16%)
PFE   28.55 (-0.80%)
PYPL   59.36 (+0.71%)
XOM   99.36 (-0.19%)
S&P 500   4,620.31 (+0.35%)
DOW   36,356.12 (+0.30%)
QQQ   395.62 (+0.88%)
AAPL   192.82 (-1.48%)
MSFT   369.84 (-1.17%)
META   324.46 (-2.49%)
GOOGL   132.52 (-1.83%)
AMZN   145.93 (-1.01%)
TSLA   240.35 (-1.43%)
NVDA   469.11 (-1.25%)
NIO   7.69 (+4.20%)
BABA   71.49 (-0.90%)
AMD   134.39 (+4.24%)
T   16.69 (-1.36%)
F   11.13 (+1.09%)
MU   78.44 (+4.64%)
CGC   0.76 (-5.50%)
GE   120.17 (-0.35%)
DIS   92.16 (-0.71%)
AMC   7.08 (+2.16%)
PFE   28.55 (-0.80%)
PYPL   59.36 (+0.71%)
XOM   99.36 (-0.19%)
S&P 500   4,620.31 (+0.35%)
DOW   36,356.12 (+0.30%)
QQQ   395.62 (+0.88%)
AAPL   192.82 (-1.48%)
MSFT   369.84 (-1.17%)
META   324.46 (-2.49%)
GOOGL   132.52 (-1.83%)
AMZN   145.93 (-1.01%)
TSLA   240.35 (-1.43%)
NVDA   469.11 (-1.25%)
NIO   7.69 (+4.20%)
BABA   71.49 (-0.90%)
AMD   134.39 (+4.24%)
T   16.69 (-1.36%)
F   11.13 (+1.09%)
MU   78.44 (+4.64%)
CGC   0.76 (-5.50%)
GE   120.17 (-0.35%)
DIS   92.16 (-0.71%)
AMC   7.08 (+2.16%)
PFE   28.55 (-0.80%)
PYPL   59.36 (+0.71%)
XOM   99.36 (-0.19%)
S&P 500   4,620.31 (+0.35%)
DOW   36,356.12 (+0.30%)
QQQ   395.62 (+0.88%)
AAPL   192.82 (-1.48%)
MSFT   369.84 (-1.17%)
META   324.46 (-2.49%)
GOOGL   132.52 (-1.83%)
AMZN   145.93 (-1.01%)
TSLA   240.35 (-1.43%)
NVDA   469.11 (-1.25%)
NIO   7.69 (+4.20%)
BABA   71.49 (-0.90%)
AMD   134.39 (+4.24%)
T   16.69 (-1.36%)
F   11.13 (+1.09%)
MU   78.44 (+4.64%)
CGC   0.76 (-5.50%)
GE   120.17 (-0.35%)
DIS   92.16 (-0.71%)
AMC   7.08 (+2.16%)
PFE   28.55 (-0.80%)
PYPL   59.36 (+0.71%)
XOM   99.36 (-0.19%)

Cytek Biosciences (CTKB) Stock Price, News & Analysis

$7.72
+0.06 (+0.78%)
(As of 02:15 PM ET)
Compare
Today's Range
$7.47
$7.75
50-Day Range
$4.10
$7.66
52-Week Range
$3.80
$13.77
Volume
331,600 shs
Average Volume
1.01 million shs
Market Capitalization
$1.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.33

Cytek Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
34.9% Upside
$10.33 Price Target
Short Interest
Bearish
7.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$593,800 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.12) to ($0.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

779th out of 943 stocks

Medical Devices Industry

4th out of 6 stocks


CTKB stock logo

About Cytek Biosciences Stock (NASDAQ:CTKB)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CTKB Stock Price History

CTKB Stock News Headlines

Is This The Most Overlooked Gold Investment Strategy of 2024?
There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Massive Insider Trade At Cytek Biosciences
What Wall Street expects from Cytek Biosciences,'s earnings
See More Headlines
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTKB
Fax
N/A
Employees
688
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.33
High Stock Price Target
$14.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+34.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$2.58 million
Pretax Margin
-8.58%

Debt

Sales & Book Value

Annual Sales
$183.12 million
Cash Flow
$0.07 per share
Book Value
$3.16 per share

Miscellaneous

Free Float
113,997,000
Market Cap
$1.04 billion
Optionable
Not Optionable
Beta
1.32
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Wenbin Jiang Ph.D. (Age 59)
    President, CEO & Chairman of the Board
    Comp: $964.21k
  • Dr. Ming Yan Ph.D. (Age 60)
    CTO & Director
    Comp: $616.26k
  • Ms. Valerie T. Barnett J.D. (Age 48)
    General Counsel & Corporate Secretary
    Comp: $535.98k
  • Mr. Patrik Sebastian Jeanmonod (Age 57)
    Chief Financial Officer
    Comp: $412.54k
  • Mr. Chris Williams (Age 54)
    Chief Operating Officer
  • Mr. Paul D. Goodson
    Head of Investor Relations
  • Dr. Allen B. Poirson Ph.D. (Age 63)
    Senior Vice President of Business & Corporate Development
  • Dr. Philippe Busque Ph.D.
    Senior Vice President of Global Sales & Services
  • Ms. Connie Wedel
    Chief People Officer
  • Mr. Melik Ulusu
    Senior Vice President of Operations & Integrated Supply Chain














CTKB Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytek Biosciences stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CTKB shares.
View CTKB analyst ratings
or view top-rated stocks.

What is Cytek Biosciences' stock price target for 2024?

4 equities research analysts have issued 1 year target prices for Cytek Biosciences' stock. Their CTKB share price targets range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.33 in the next year. This suggests a possible upside of 34.9% from the stock's current price.
View analysts price targets for CTKB
or view top-rated stocks among Wall Street analysts.

How have CTKB shares performed in 2023?

Cytek Biosciences' stock was trading at $10.21 on January 1st, 2023. Since then, CTKB shares have decreased by 25.0% and is now trading at $7.66.
View the best growth stocks for 2023 here
.

Are investors shorting Cytek Biosciences?

Cytek Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 8,380,000 shares, an increase of 5.8% from the October 31st total of 7,920,000 shares. Based on an average daily trading volume, of 1,070,000 shares, the short-interest ratio is currently 7.8 days. Currently, 7.2% of the company's stock are sold short.
View Cytek Biosciences' Short Interest
.

When is Cytek Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CTKB earnings forecast
.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.02. The company had revenue of $48 million for the quarter, compared to analysts' expectations of $55.09 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 1.73% and a negative net margin of 7.61%.

What ETF holds Cytek Biosciences' stock ?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio.

When did Cytek Biosciences IPO?

(CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

Who are Cytek Biosciences' major shareholders?

Cytek Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (4.99%), New York State Common Retirement Fund (1.72%), Wellington Management Group LLP (1.07%), Northern Trust Corp (0.84%), Charles Schwab Investment Management Inc. (0.61%) and Bank of New York Mellon Corp (0.61%). Insiders that own company stock include Jack Ball, Ming Yan, Patrik Jeanmonod, Ra Capital Management, LP and Wenbin Jiang.
View institutional ownership trends
.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CTKB) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -